PMV Pharma Q3 net loss $19.2M; cash runway to end 2026; Phase 2 enrollment on track

PMV Pharmaceuticals, Inc.

2024-Q3 EPS reported -$0.69

Net loss $19.2M in Q3 2024 vs $16.6M Q3 2023; R&D spend rose to $16.9M on trial costs.
Cash $197.9M at Sep 30, 2024; provides expected runway to end of 2026.
Phase 2 PYNNACLE trial enrollment on track; >75% sites activated; interim analysis expected mid-2025.
Investigator-initiated Phase 1b of rezatapopt in AML/MDS with MD Anderson and MSKCC; enrollment planned Q1 2025.
Discontinued Phase 1b combination arm with pembrolizumab due to dose-limiting toxicities and limited benefit.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.